Next Decade in Early Clinical Development:
The most impactful cocktail of scientific innovation and unconventional operations with focus on patients
Join Arensia for a unique day of learning, networking and a drinks reception.
Meet the Speaker
Conversation will be lead by our expert facilitators
Dr. Claudia Hesselmann, PhDCo-founder & CEO ARENSIA EXPORATORY MEDICINE GMBH
More about ARENSIA Exploratory Medicine
ARENSIA EXPLORATORY MEDICINE is a German operator of proprietary research clinics in Eastern Europe, dedicated to performing complex Phase Ib, IIa and proof-of-concept clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to dramatically reduce the overall number of sites, countries and recruitment periods for any early phase patient trial. Sponsors regard the recruiting speed and the data quality of ARENSIA as disruptive added value, providing them with a strategic advantage. As a testament to the excellent performance, ARENSIA is trusted by the world’s largest pharmaceutical and biotechnology companies, by global CROs, as well as by venture capital funds aiming to maximize their return of investment in small/virtual biotech companies. At ARENSIA, we are serving a variety of therapeutic areas, with key expertise in: oncology, immuno-inflammation, neurosciences, cardiology, respiratory, dermatology, infectious diseases, gastro-enterology, metabolics.